NFKB1 and pulmonary fibrosis: In vivo experiments in mice have shown that AK-7 targets SIRT-2 by inhibiting the NF-κB signaling pathway on T cells, thereby inhibiting airway inflammation and oxidative damage, slowing down collagen deposition and pulmonary fibrosis in COPD mice (121), and NF-κB inhibitor SP100030 inhibited the activity of T cells could reduce the immune microenvironment inflammation and also could upregulate fibroblast activation, proliferation, and collagen deposition in lungs of mice (128).